Categories
Change Password!
Reset Password!
Single-dose intravenous ferric derisomaltose rapidly restores hemoglobin and iron stores, significantly reducing postpartum anemia when compared with conventional iron therapy.
Postpartum hemorrhage (PPH), a leading cause of acute iron deficiency anemia in new mothers, can markedly impact maternal health, contributing to fatigue, depression, and challenges with breastfeeding. Addressing this urgent clinical need, a new retrospective observational study has demonstrated that a single high-dose intravenous iron therapy may offer faster and more effective recovery than conventional treatment.
The study, led by Takuya Misugi et al, evaluated 91 postpartum women whose hemoglobin levels fell below 8 g/dL within 3 days after delivery. The enrolled subjects were segregated into 2 groups:
Researchers assessed key hematologic parameters—including hemoglobin, serum iron, ferritin, total iron-binding capacity, reticulocyte count, and serum phosphate—at 2 weeks and 1 month postpartum. Results of this real-world study revealed that women treated with FDI achieved remarkably higher hemoglobin levels and lower anemia rates at both checkpoints as opposed to the conventional therapy group. Serum iron and ferritin concentrations were also markedly higher in the FDI group, indicating more rapid replenishment of iron stores.
Notably, no cases of hypophosphatemia were noted in either treatment group, underscoring the favorable safety profile of FDI. To sum up, single-dose intravenous FDI not only accelerates the correction of postpartum anemia but also simplifies treatment by diminishing the need for multiple administrations. These findings suggest that FDI could become a preferred real-world option for mitigating postpartum iron deficiency, improving recovery and maternal well-being.
Cureus
Real-World Comparative Effectiveness of Ferric Derisomaltose Versus Conventional Iron Treatment in Postpartum Hemorrhage-Related Anemia
Takuya Misugi et al.
Comments (0)